[Use of Kovaltry® in patients with Hemophilia A: clinical and economical aspects from the pivotal clinical trials]
DOI:
https://doi.org/10.7175/fe.v18i1.1284Keywords:
Hemophilia A, Recombinant factor VIII, KovaltryAbstract
[Article in Italian]References
Barr RD, Saleh M, Furlong W, et al. Health status and health-related quality of life associated with hemophilia. Am J Hematol 2002; 71: 152-60; https://doi.org/10.1002/ajh.10191
Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10; https://doi.org/10.1111/j.1538-7836.2011.04214.x
Gringeri A, Leissinger C, Cortesi PA, et al. Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study. Haemophilia 2013; 19: 736-43; https://doi.org/10.1111/hae.12178
Valentino LA, Hakobyan N, Enockson, et al. Exploring the biological basis of haemophilic joint disease: experimental studies. Haemophilia 2012; 18: 310-8; https://doi.org/10.1111/j.1365-2516.2011.02669.x
Noone D, O’Mahony B, van Dijk JP, et al. A survey of the outcome of prophylaxis, on-demand treatment or combined treatment in 18-35-year old men with severe haemophilia in six countries. Haemophilia 2013; 19: 44-50; https://doi.org/10.1111/j.1365-2516.2012.02934.x
Ar MC, Baslar Z, Soysal T. Personalized prophylaxis in people with hemophilia A: challenges and achievements. Expert Rev Hematol 2016; 9: 1203-8; https://doi.org/10.1080/17474086.2016.1252670
Kodra Y, Cavazza M, Schieppati A, et al. The social burden and quality of life of patients with haemophilia in Italy. Blood Transfus 2014; 12 Suppl 3: s567-75; https://doi.org/10.2450/2014.0042-14s
Rocino A, Cortesi PA, Scalone L, et al.; European Haemophilia Therapy Strategy Board (EHTSB). Immune tolerance induction in patients with haemophilia a and inhibitors: effectiveness and cost analysis in an European Cohort (The ITER Study). Haemophilia 2016; 22: 96-102; https://doi.org/10.1111/hae.12780
Abbonizio F, Giampaolo A, Coppola A, et al.; Italian Association of Haemophilia Centres. Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy. Haemophilia 2014; 20: e243-50; https://doi.org/10.1111/hae.12456
Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost 2015; 13: 360-9; https://doi.org/10.1111/jth.12828
Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and Safety of BAY 81-8973, a full length recombinant factor VIII: results from the LEOPOLD I. Haemophilia 2016; 22: 706-12; https://doi.org/10.1111/hae.12952
Mahlangu J, Powell JS, Ragni MV, et al. Phase 3 study of recombinant factor VIII Fc fusion protein in severe hemophilia A. Blood 2014; 123: 317-25; https://doi.org/10.1182/blood-2013-10-529974
Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia 2013; 19: 691-7; https://doi.org/10.1111/hae.12159
Ozelo M, Misgav M, Abdul Karim F, et al. Long-term patterns of safety and efficacy of bleeding prophylaxis with turoctocog alfa (NovoEight(®)) in previously treated patients with severe haemophilia A: interim results of the guardian(™) 2 extension trial. Hemophilia 2015; 21: e436-9; https://doi.org/10.1111/hae.12737
Lentz SR, Cerqueira M, Janic D, et al. Interim results from a large multinational extension trial (guardian(™) 2) using turoctocog alfa for prophylaxis and treatment of bleeding in patients with severe haemophilia A. Haemophilia 2016; 22: e445-9; https://doi.org/10.1111/hae.12990
Tiede A, Oldenburg J, Lissitchkov T, et al. Prophylaxis vs. on-demand treatment with Nuwiq(®) (Human-cl rhFVIII) in adults with severe haemophilia A. Haemophilia 2016; 22: 374-80; https://doi.org/10.1111/hae.12859
Hermans C, Klamroth R, Richards M, et al. Outcome measures in European patients with haemophilia: Survey of implementation in routine clinical practice, perception of relevance and recommendations by European treaters in the EHTSB. Haemophilia 2016 [Epub ahead of print]; https://doi.org/10.1111/hae.13085
Published
How to Cite
Issue
Section
License
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. The Publication Agreement can be downloaded here, and should be signed by the Authors and sent to the Publisher when the article has been accepted for publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (see The Effect of Open Access).
- Authors are permitted to post their work online after publication (the article must link to publisher version, in html format)
